NEXMED AND ÅNGSTROM PHARMACEUTICALS TO PRESENT ON Å6 DRUG AT AACR
San Diego--(BUSINESS WIRE)-- NexMed, Inc. (Nasdaq: NEXM), a specialty CRO with a pipeline of products based on the NexACT® technology, today announced that Bio-Quant, its wholly-owned subsidiary, and Ångstrom Pharmaceuticals, a privately-held pharmaceutical company, will jointly present data at the 101st Annual Meeting of the American Association for Cancer Research (AACR), in Washington, D.C. from April 17-21, 2010. The poster presentation, entitled, "Å6 peptide binds to CD44 and inhibits migration and metastasis of CD44+ cell lines in in vitro and in vivo studies," covers pre-clinical work completed by Bio-Quant on Ångstrom's lead product, Å6, currently in Phase 2 development for ovarian cancer.
Bassam Damaj, Ph.D., President and Chief Executive Officer of NexMed, and one of the presenters at AACR, stated, "We are pleased to have supported Ångstrom in their target identification of the Å6 drug. Å6 has demonstrated activity in in vitro models of cell migration, invasion and angiogenesis, as well as in breast, prostate and brain tumor models. Similar activity was also seen in animal models of ocular disease. The results support the efficacy of Å6 across various cancer cells, which suggests that the drug is addressing a fundamental pathway for proliferative and invasive diseases."
Malcolm Finlayson, Ph.D., President and Chief Executive Officer of Ångstrom, noted, "The work done by NexMed's Bio-Quant team on behalf of Ångstrom is a testament to their expertise in the field of oncology. We look forward to the results of the ongoing studies on the mechanism of action of Å6."
About Ångstrom Pharmaceuticals and Å6
Based in San Diego, CA, Ångstrom is developing a new class of drugs targeting CD44 for the treatment of diseases involving cell migration, invasion, and metastasis. Results from a completed Phase 1a safety clinical trial on Å6 showed there were no systemic drug-related adverse events in healthy volunteers. Ångstrom has also successfully completed a Phase 1b clinical trial evaluating Å6 in women with advanced gynecologic cancer, and a Phase 2 clinical trial evaluating Å6 in women with asymptomatic CA125 progression of epithelial ovarian cancer after first-line chemotherapy. Treatments were well tolerated and more than 40% of the patients dosed continuously with Å6 experienced disease stabilization. For further information, go to www.angstrominc.com.
About NexMed, Inc.
NexMed is the largest specialty CRO based in San Diego, CA and is one of the industry's most experienced CROs for in vitro and in vivo pharmacology services and research models. The Company's goal is to generate revenues from the growth of its Discovery Pre-clinical CRO business, while aggressively seeking to monetize its proprietary NexACT® drug delivery technology through out-licensing agreements with pharmaceutical and biotechnology companies, worldwide. At the same time, NexMed is actively pursuing partnering opportunities for its NexACT-based treatments for onychomycosis, psoriasis, sexual dysfunction and cancer. For further information on NexMed and its subsidiaries, visit the following websites: http://www.nexmed.com or http://www.bio-quant.com.
Edward Cox, V.P.
Investor Relations & Corporate Development NexMed, Inc.
Angstrom Pharmaceuticals, Inc.
Ph.D., President and CEO
NexMed Investor Relations
NexMed, Inc. Rx Communications Group, LLC